

# BuyersStrike!

## It Was Dark Over Westphalia

### But Teh Science Be So Gud: Part 1 – A Brief History of Loserlimab (CYDY)

There is one talking point that almost every bioscam on the verge of collapse eventually reaches for, known at **BuyersStrike! HQ** as “but teh science be so gud.” We have reached that moment in the saga of everyone’s favorite reverse-merger pink sheet Coronacrappier, **Cytodyn (CYDY)**, when criminal stock promoters, various shills, and the retail shareholder base of complete morons suddenly become “experts” in “teh science”.

So, while we wait for the next delusional ranting from **The NaDDir\***, and while we wait for the company to fess up that their quest for a Nasdaq listing is clearly doomed, (<https://buyersstrike.wordpress.com/2020/08/20/what-exchange-wont-cytodyn-be-listed-on-this-week-cydy/>), in this series we’ll explore “teh science” behind **leronlimab** (hereafter known as **loserlimab**), and explain how it is basically completely useless.

Useless against HIV.

Useless against Cancer

And yes, even utterly useless against Covid-19.

First, we’ll look at the history of **loserlimab** and what it does, and doesn’t do, with regards to HIV.

Far from being a new drug, **loserlimab** can trace its roots back to the late 1990s. Scientists discovered that people carrying a particular genetic mutation, known as “**Delta 32**” were immune to infection by **one strain** of HIV (known as “**CCR5-Tropic**” HIV). People carrying this mutation did not express the CCR5 receptor on the outside of their cells. This gave the CCR5-tropic HIV particles nowhere to latch onto in order to enter the cell.

After this discovery scientists rushed to create treatments that would mimic this genetic mutation. In 2007 the first of them, **Selzentry** (also known generically as **maraviroc**) was approved for sale in the USA. **Selzentry** blocks the CCR5 receptor on the outside of cells, stopping CCR5-Tropic HIV from entering and doing their nasty business.

**Selzentry** is a daily pill that is taken **in combination** with other daily medications. Why in combination? Because as explained above **blocking CCR5 only stops one form of HIV**. CCR5 blocking monotherapy is a **mono-mentally (sic) stupid** idea in practice because it would fail to protect from the **other** form of HIV, known as **CXCR4-Tropic**. Any company, any tout, any deluded investor who believes that monotherapy to block only CCR5 would be a real breakthrough, and have any commercial potential, is either a con artist, or a mark.

Although it happens to be the only one to successfully make it onto the market, **maraviroc** was not the only therapy developed back in the late 90s. There were many other attempts. One scientist who was working on such therapies was **William Olson**. Along with **Paul Maddon** and others at **Progenics Pharmaceuticals (PGNX)** he developed a series (<https://pubmed.ncbi.nlm.nih.gov/10196311/>), of murine (mouse) antibodies to block CCR5. One of them was originally known as **PA14**.

**Progenics** then hired another firm, **Protein Design Labs**, to “humanize” the antibody. This process makes antibodies developed in other species, like mice, more tolerable (technically less “immunogenic”) in human patients. The resulting humanized antibody was christened **PRO-140**.

PRO-140 had some interesting attributes. For one, it **did not completely block CCR5 receptors**. It only bound to a very small part of the CCR5 receptor, just the part necessary for **one particular strain** of HIV to enter the cell. PRO-140 also does not interfere with normal CCR5 receptor functions. According to **Olson** (<https://grantome.com/grant/NIH/R44-AI046871-05>):

*“Moreover, unlike other candidate CCR5 inhibitors, PRO 140 does not block CCR5’s natural activity”*

And, because this is a very important point that bears repeating, in **another paper** (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC113953/>), by **Olson** and **Maddon**, from 2001:

*Because PRO 140 does not induce signaling or downregulation of CCR5, its antiviral effect is probably exerted through a mechanism involving receptor blockade.*

Eventually, after playing around with both IV and subcutaneous administration, and seeing the approval of more convenient oral **Selzentry** (remember that CCR5 blocking therapy **MUST** be given in combination with other medications in order to treat and block **both** forms of HIV), **Progenics** gave up on PRO-140. After putting it on the shelf, a small desperate reverse merger abomination known as **Cytodyn** came calling, bought it for a small sum, and renamed it **leronlimab**.

Hopefully, dear reader, you can now see that **loserlimab** is actually **fairly useless against HIV**, because **it does not protect against both strains**. At best one could say that it **might** protect against only one (the jury is still out, as the drug has not been approved anywhere, for this purpose).

But, but, cry the Cytodummies, what about the plan to “cure” AIDS patients getting bone marrow transplants by adding **Isoerlimab**, announced two weeks ago?

08/17/2020 06:15:02 [PZM]

## CytoDyn Will Attempt to Duplicate Berlin and London Patients’ HIV Cure by Using Leronlimab During Bone Marrow Transplant for 5 HIV Patients who also have Cancer

Yeah, that won’t work either. Why not? Because **it will not protect from the other form of HIV**. And this has been known for years (<https://www.nejm.org/doi/full/10.1056/NEJMc1405805>).

As for cancer, Covid, and the rest? Stay tuned...

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

\*

Posted in [Bad Directors](#), [Bio-Dreck](#), [Bucket Shops](#), [CoronaCrap](#), [Reverse Mergers](#) on [August 28, 2020](#) by [BuyersStrike!](#) [22 Comments](#)

## 22 comments

1. **bluefish** says:

[August 28, 2020 at 9:56 pm](#)

What a monumental failure to even understand the science of why HIV and AIDS do what they do, how infection occurs, and how the disease progresses. To top it off, you link to some article behind a pay wall. Leronlimab helps keep HIV from progressing in the first place. But please don’t read the results from Cytodyn’s phase 3 HIV study, and please disregard the fact that study participants that chose to remain on Leronlimab remain virus free for multiple years post study, without taking their other HIV medications.

But nice try. You’re also bigoted for continuing to purposely butcher Dr. Pourhassan’s name. What a low life piece of trash.

What utter nonsense will you post next? The world awaits, I’m sure.

### REPLY

1. **BuyersStrike!** says:

[August 28, 2020 at 11:44 pm](#)

Poor deluded Bluefish. Everyone here at HQ has read the “results” from Cytodyn’s Phase 3 study. You know, the only completed P3 study the company has ever managed to do, the study that **evaluated Isoerlimab in COMBINATION** with other drugs, **only enrolled 25 patients**, had **no control group**, and **only included patients with CCR5-Tropic HIV**, not any patients with the other strain of HIV. That trial? You might want to read it again. This time more carefully.

## REPLY

### 1. bluefish says:

[August 29, 2020 at 12:45 am](#)

Incorrect, so incorrect. Do better research before spouting off your nonsense. Poor deluded loser.

<https://www.clinicaltrials.gov/ct2/show/NCT02859961?cond=pro140&draw=3&rank=11>

THIS trial.

500 patients, not 25. Still enrolling, still treating and helping people with HIV. READ UP, and don't be ignorant your entire life.

Did you purposely forget to look at that trial, or do you just not know how to look up stuff? Your level of fail is quite epic. But please, keep going.

HIV tropism is normally in advanced stages of the disease. Mostly people don't "catch" T-tropic HIV. Treating HIV successfully early on makes it less likely the disease will progress to full AIDS. Stop spouting off about your ignorance.

### 2. BuyersStrike! says:

[August 29, 2020 at 12:59 am](#)

That 500 person trial you mention **doesn't have any results yet**, dum-dum. You **cannot make any efficacy claims based on a trial that hasn't been completed yet!** The only P3 trial by Cytodyn with any results is their pathetic 25 patient trial. And **no matter what form of HIV one contracts, it is always going to be "-tropic"**, either CCR5-tropic or CXCR4-tropic. Whether at the initial infection stage, the latency stage, or full blown AIDS stage. Loserlimab, at best, could only possibly work against ONE strain of HIV, CCR5-Tropic. It has absolutely zero utility against CXCR4-Tropic HIV. None.

Loserlimab isn't helping anybody with anything. For a **real HIV treatment**, that is effective against both CCR5- and CXCR4-tropic HIV, you can find it already on the market, it is called **Trogarzo**, and has been available for over 2 years.

2. Pingback: [Quick Take: Who's Not Participating in Cytodyn's Ridiculous Loserlimab Trial? \(CYDY\) | BuyersStrike!](#)

### 3. Jack Crosby says:

[September 9, 2020 at 4:48 pm](#)

You have the writing skills of a small, Autistic child with dyslexia. Do you honestly believe that anyone would take this mindless drivel seriously?? If your goal was to cast doubt about the remarkable efficacy of Lerolimab, I regret to inform you that you've failed miserably.

[Yet somehow you keep reading. Point out an actual error of fact and we'll get an intern right on it, until then we'll be at 100% full snark mode. -- Editor]

## REPLY

4. Pingback: [Just Who IS Participating in Cytodyn's Loserlimab Coronavirus Trial? \(CYDY\) | BuyersStrike!](#)

5. Pingback: [The Death Tape \(CYDY\) | BuyersStrike!](#)

6. Pingback: [Who Else Is Suing Cytodyn Now? \(CYDY\) | BuyersStrike!](#)

7. Pingback: [Reader Mailbag - Breakthrough Therapy Edition \(CYDY\) | BuyersStrike!](#)

8. Pingback: [Who's STILL Not Participating in CYTODYN'S Ridiculous Loserlimab Trial? \(CYDY\) | BuyersStrike!](#)

9. Pingback: [Quick Take: What Cytodelusion Actually Died Last Night? \(CYDY\) | BuyersStrike!](#)

10. Pingback: [Update: Guess Who is \(yet again\) still not participating in the Loserlimab Trial? \(CYDY\) | BuyersStrike!](#)

11. Pingback: [Sunday Funday - What Else Doesn't Cytodyn Want Investors To Learn? \(CYDY\) | BuyersStrike!](#)

12. Pingback: [Christmas Week Quick Take: What Misleading BS is Cytodyn Spewing Today? \(CYDY\) | BuyersStrike!](#)

13. Pingback: [Christmas Week Quick Take 2: What NASDAQ Listing Nonsense Are The Cytodyn Shills Spewing Today? \(CYDY\) | BuyersStrike!](#)

14. Pingback: [Christmas Eve Quick Take: Who clearly has no clue what an Open Label Extension is? \(CYDY\) | BuyersStrike!](#)

15. Pingback: [Who's Suing Cytodyn Now? \(CYDY\) | BuyersStrike!](#)

16. Pingback: [Which Country Will Not Be Granting Cytodyn an EUA Anytime Soon? \(CYDY\) | BuyersStrike!](#)

17. Pingback: [What Other Disease Won't Cytodyn Be Curing Today? \(CYDY\) | BuyersStrike!](#)

18. Pingback: [NYE Quick Take: What Journal Article Did Cytodyn Pay To Get Published Today? \(CYDY\) | BuyersStrike!](#)

19. Pingback: [Cytodyn CONFERENCE Call Preview \(CYDY\) | BuyersStrike!](#)

This site uses Akismet to reduce spam. [Learn how your comment data is processed.](#)

[BLOG AT WORDPRESS.COM.](#)